Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JM-4 in Multiple Sclerosis/Clinically Isolated Syndrome
NCT03887065Phase 1Unknown
- Start
- Jun 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of JM-4 in multiple sclerosis (MS) and clinically isolated syndrome (CIS) (3 arms). Primary endpoints: Number of patients with treatment-related adverse events at 8 days and Change in GAD(+) brain lesions measured via MRI scan at 8 days. Status: unknown.
02
Drugs
JM-4
03
Conditions
multiple sclerosis (MS)clinically isolated syndrome (CIS)
Beyond the preview
Go deeper on NCT03887065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03887065.